福瑞医科(300049) - 2025 Q4 - 年度业绩预告

Financial Projections - The estimated net profit attributable to shareholders for 2025 is projected to be between 135 million and 164 million CNY, representing a year-on-year increase of 19.17% to 44.77% compared to 113.29 million CNY in 2024[3] - The estimated net profit after deducting non-recurring gains and losses is expected to be between 127 million and 166 million CNY, reflecting a year-on-year growth of 7.89% to 41.02% from 117.72 million CNY in the previous year[3] - The net profit from the French subsidiary's medical device business is expected to be between 220 million and 260 million CNY, indicating a year-on-year increase of 15.48% to 36.47%[5] - The company aims to achieve revenue of approximately 450 million to 480 million CNY from its managed medical services and other businesses, with an estimated net profit attributable to shareholders of about 25 million to 34 million CNY[5] - The impact of non-recurring gains and losses on net profit is estimated to be between -2 million and -8 million CNY for the year 2025[5] Revenue Expectations - The medical device business of the French subsidiary is anticipated to generate revenue of approximately 1.05 billion to 1.20 billion CNY, with a year-on-year growth of about 13.77% to 30.02%[5] Performance Forecast - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited[6] - The company has communicated with the auditing firm regarding the performance forecast, and there are no significant disagreements[4] - Investors are advised to make cautious decisions and be aware of investment risks as the financial data will be finalized in the 2025 annual report[7] - The performance forecast period is from January 1, 2025, to December 31, 2025[3]